BioCryst Pharmaceuticals has secured a $34.7m contract from the US Centers for Disease Control and Prevention (CDC) for the supply of up to 50,000 doses of its approved antiviral influenza therapy, RAPIVAB (peramivir injection) over a five-year period.
The CDC’s purchase of RAPIVAB will supply the Strategic National Stockpile, the nation’s largest supply of potentially life-saving pharmaceuticals and medical supplies for use in a public health emergency.
BioCryst CEO Jon Stonehouse said: “We appreciate the CDC acknowledging the value of RAPIVAB to patients and our national security.
“Peramivir continues to be a source of non-dilutive capital for BioCryst and we will use these additional resources to support advancement of our exciting pipeline,” Stonehouse added.
Source: Company Press Release